Research Blogs

While our bodies can have a wide range of naturally occurring, harmless mutations in different genes, some mutations, called driver mutations, are key to driving the development of cancer. In the early 2000s, EGFR was the first gene in non-small cell lung cancer (NSCLC) to be matched with a targeted therapy.

It is hard to believe that we’re already in November and celebrating Lung Cancer Awareness Month! In addition to recognizing LCAM, fall is also a good time to remind people

On June 1st, 2022, LUNGevity Foundation hosted a Facebook Live to discuss our manuscript titled “ The 2021 Global Lung Cancer Therapy Landscape” published in the Journal of

The American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago June 3-7, 2022. Dr. Upal Basu Roy, Executive Director of Research at LUNGevity Foundation, sat down with Dr. Charles Rudin to discuss key highlights from ASCO 2022 and what they mean for the lung cancer community.

MET is a gene that encodes for a MET protein. It is an important signaling protein known to play many different important roles, from the development of embryos to wound healing in

Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the

Some people with lung cancer have reduced lung function from their cancer or their treatments, like surgery, radiation, or chemotherapy. People with diminished lung functional

Good mental health, or our emotional, psychological, and social well-being, is essential for overall health. Being diagnosed and living with cancer, however, can impact our mental

This article is intended to be used for informational purposes and not to be taken as medical advice. The piece was reviewed for accuracy by Dr. Richard Dunne, MD, medical

53 days after Julie Jones had video assisted thoracic surgery (VATS) to remove the lower lobe of her right lung, Julie ran a half marathon. Even more impressive, she finished only

According to the National Cancer Institute, approximately 70% of lung cancer patients are initially diagnosed with advanced-stage disease, which is more difficult to treat than

Immunotherapy, the treatment that harnesses the body’s natural defenses to fight disease, has helped patients, excited imaginations, and stimulated new avenues of research in lung